Literature DB >> 16507771

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.

Esther A Obeng1, Louise M Carlson, Delia M Gutman, William J Harrington, Kelvin P Lee, Lawrence H Boise.   

Abstract

Multiple myeloma (MM) is an incurable plasma cell malignancy. The 26S proteasome inhibitor, bortezomib, selectively induces apoptosis in MM cells; however, the nature of its selectivity remains unknown. Here we demonstrate that 5 different MM cell lines display similar patterns of sensitivity to 3 proteasome inhibitors (PIs) but respond differently to specific NF-kappaB inhibition. We further show that PIs initiate the unfolded protein response (UPR), a signaling pathway activated by the accumulation of misfolded proteins within the endoplasmic reticulum (ER). Consistent with reports that prosurvival/physiologic UPR components are required for B-cell differentiation into antibody-secreting cells, we found that MM cells inherently expressed the ER chaperones GRP78/Bip and GRP94/gp96. However, bortezomib rapidly induced components of the proapoptotic/terminal UPR, including PERK, the ER stress-specific eIF-2alpha kinase; ATF4, an ER stress-induced transcription factor; and its proapoptotic target, CHOP/GADD153. Consistent with our hypothesis that PIs induce the accumulation of misfolded ER-processed proteins, we found that the amount of immunoglobulin subunits retained within MM cells correlated with their sensitivity to PIs. These findings suggest that MM cells have a lower threshold for PI-induced UPR induction and ER stress-induced apoptosis because they constitutively express ER stress survival factors to function as secretory cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16507771      PMCID: PMC1895817          DOI: 10.1182/blood-2005-08-3531

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  99 in total

Review 1.  Posttranslational quality control: folding, refolding, and degrading proteins.

Authors:  S Wickner; M R Maurizi; S Gottesman
Journal:  Science       Date:  1999-12-03       Impact factor: 47.728

Review 2.  Setting the standards: quality control in the secretory pathway.

Authors:  L Ellgaard; M Molinari; A Helenius
Journal:  Science       Date:  1999-12-03       Impact factor: 47.728

3.  Cutting edge: proteasome involvement in the degradation of unassembled Ig light chains.

Authors:  T O'Hare; G D Wiens; E A Whitcomb; C A Enns; M B Rittenberg
Journal:  J Immunol       Date:  1999-07-01       Impact factor: 5.422

4.  BiP and immunoglobulin light chain cooperate to control the folding of heavy chain and ensure the fidelity of immunoglobulin assembly.

Authors:  Y K Lee; J W Brewer; R Hellman; L M Hendershot
Journal:  Mol Biol Cell       Date:  1999-07       Impact factor: 4.138

5.  Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin.

Authors:  P Masdehors; S Omura; H Merle-Béral; F Mentz; J M Cosset; J Dumont; H Magdelénat; J Delic
Journal:  Br J Haematol       Date:  1999-06       Impact factor: 6.998

Review 6.  Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls.

Authors:  R J Kaufman
Journal:  Genes Dev       Date:  1999-05-15       Impact factor: 11.361

7.  Evidence for distinct intracellular signaling pathways in CD34+ progenitor to dendritic cell differentiation from a human cell line model.

Authors:  D C St Louis; J B Woodcock; G Franzoso; P J Blair; L M Carlson; M Murillo; M R Wells; A J Williams; D S Smoot; S Kaushal; J L Grimes; D M Harlan; J P Chute; C H June; U Siebenlist; K P Lee; G Fransozo
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

8.  Proteasome inhibitors: a novel class of potent and effective antitumor agents.

Authors:  J Adams; V J Palombella; E A Sausville; J Johnson; A Destree; D D Lazarus; J Maas; C S Pien; S Prakash; P J Elliott
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

9.  Caspase-mediated cleavage of eukaryotic translation initiation factor subunit 2alpha.

Authors:  S Satoh; M Hijikata; H Handa; K Shimotohno
Journal:  Biochem J       Date:  1999-08-15       Impact factor: 3.857

10.  Mammalian unfolded protein response inhibits cyclin D1 translation and cell-cycle progression.

Authors:  J W Brewer; L M Hendershot; C J Sherr; J A Diehl
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

View more
  460 in total

1.  PRDM1 is required for mantle cell lymphoma response to bortezomib.

Authors:  Shruti Desai; Michelle Maurin; Matthew A Smith; Sophia C E Bolick; Sophie Dessureault; Jianguo Tao; Eduardo Sotomayor; Kenneth L Wright
Journal:  Mol Cancer Res       Date:  2010-06-08       Impact factor: 5.852

2.  KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.

Authors:  Sudha Mannava; DaZhong Zhuang; Jayakumar R Nair; Rajat Bansal; Joseph A Wawrzyniak; Shoshanna N Zucker; Emily E Fink; Kalyana C Moparthy; Qiang Hu; Song Liu; Lawrence H Boise; Kelvin P Lee; Mikhail A Nikiforov
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

Review 3.  Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.

Authors:  Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Journal:  Mol Cancer Ther       Date:  2011-11       Impact factor: 6.261

4.  Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.

Authors:  Hyun Joo Jung; Zheng Chen; Michael Wang; Luis Fayad; Jorge Romaguera; Larry W Kwak; Nami McCarty
Journal:  Blood       Date:  2012-01-31       Impact factor: 22.113

Review 5.  New molecular targets in mantle cell lymphoma.

Authors:  Samir Parekh; Marc A Weniger; Adrian Wiestner
Journal:  Semin Cancer Biol       Date:  2011-09-18       Impact factor: 15.707

Review 6.  B cells as therapeutic targets in SLE.

Authors:  Iñaki Sanz; F Eun-Hyung Lee
Journal:  Nat Rev Rheumatol       Date:  2010-06       Impact factor: 20.543

7.  Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma.

Authors:  Kristopher A Sarosiek; Lucas E Cavallin; Shruti Bhatt; Ngoc L Toomey; Yasodha Natkunam; Wilfredo Blasini; Andrew J Gentles; Juan Carlos Ramos; Enrique A Mesri; Izidore S Lossos
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

Review 8.  The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?

Authors:  Martin McLaughlin; Koen Vandenbroeck
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

9.  Toscana virus NSs protein promotes degradation of double-stranded RNA-dependent protein kinase.

Authors:  Birte Kalveram; Tetsuro Ikegami
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

10.  Disruption of crosstalk between the fatty acid synthesis and proteasome pathways enhances unfolded protein response signaling and cell death.

Authors:  Joy L Little; Frances B Wheeler; Constantinos Koumenis; Steven J Kridel
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.